SCHEMBL3975786

SCHEMBL3975786

CCOC(=O)c1cn(CC)c2ccc(CCCNC(=O)OC(C)(C)C)c(C)c2c1=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.44
KDM4E B2RXH2 4/20 0.42
ALDH1A1 P00352 3/20 0.42
CYP1A2 P05177 1/20 0.42
HTT P42858 1/20 0.42
HPGD P15428 3/20 0.37
MAPT P10636 2/20 0.37
MEN1 O00255 1/20 0.37
THRB P10828 1/20 0.37
KMT2A Q03164 1/20 0.37
TDP1 Q9NUW8 1/20 0.37
NPSR1 Q6W5P4 1/20 0.37
POLB P06746 1/20 0.36
HSD17B10 Q99714 2/20 0.36
BRD4 O60885 3/20 0.36
CRHBP P24387 1/20 0.36
CRHR2 Q13324 1/20 0.36
CAMK2D Q13557 2/20 0.35
ADORA3 P0DMS8 1/20 0.34
ADORA2A P29274 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3983152 0.91 KDM4E (0.42) LMNAKDM4EALDH1A1CYP1A2HTT
SCHEMBL3982430 0.82 LMNA (0.56) LMNAKDM4EALDH1A1HPGDMAPT
SCHEMBL5425662 0.80 KDM4E (0.53) LMNAKDM4EALDH1A1HPGDMEN1
SCHEMBL3975902 0.80 LMNA (0.44) LMNAKDM4EALDH1A1CYP1A2HTT
SCHEMBL4392574 0.77 LMNA (0.52) LMNAKDM4EALDH1A1HPGDMAPT
SCHEMBL4173128 0.76 LMNA (0.48) LMNAKDM4EALDH1A1HPGDMAPT
SCHEMBL5432054 0.75 LMNA (0.54) LMNAKDM4EALDH1A1HPGDMAPT
SCHEMBL3818542 0.75 LMNA (0.52) LMNAKDM4EALDH1A1HPGDMAPT
SCHEMBL5255090 0.74 LMNA (0.46) LMNAKDM4EALDH1A1HPGDMAPT
SCHEMBL3816675 0.74 LMNA (0.55) LMNAKDM4EALDH1A1HPGDMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7569550-B2 14 and 15 membered ring compounds GLAXO GROUP LIMITED (GB) 2009-08-04 US disclosed
US-20070185117-A1 Novel 14 and 15 membrered ring compounds GLAXO GROUP LIMITED (GB) 2007-08-09 US disclosed
EP-1628988-B1 NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS GLAXO GROUP LTD (GB) 2006-10-04 EP disclosed
EP-1628988-A1 NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS GLAXO GROUP LIMITED (GB) 2006-03-01 EP disclosed
WO-2004101586-A1 NOVEL 14 AND 15 MEMBERED-RING COMPOUNDS GLAXO GROUP LIMITED (GB) 2004-11-25 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070185117-A1 Novel 14 and 15 membrered ring compounds CYP51A1, LSS, IL17A LMNA 2615/4885KDM4E 3840/4885ALDH1A1 2827/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.